Results 11 to 20 of about 9,005,593 (124)

Expert Report for the UK Covid-19 Public Inquiry: Module 2B: Welsh Government core political and administrative decision-making in relation to the Covid-19 pandemic [PDF]

Expect Report for the UK Covid-19 Public Inquiry: Module 2B: Welsh Government core political and administrative decision-making in relation to the Covid-19 ...
Wincott, Daniel, UK Covid-19 Public Inquiry   +1 more
core   +6 more sources

COVID-19 vaccination for people with disabilities [PDF]

, 2021
Internationally, people with disabilities have been disproportionately impacted by COVID-19, accounting for nearly 60% of COVID-19 deaths in the UK and overall higher mortality rates based on social, clinical, and demographic factors.
Stall, Nathan M, Brown, H, Katz, G, Bell, S, Rochon, P, Razak, Fahad, Lunsky, Y, Safar, Y, Downer, Matthew B, Brown, Hilary, Campanella, Sabrina, Cooper, Jane, Porch, W, Rotenberg, Sara, Rochon, Paula A, Downer, Mathew Bruce, Stall, N, Razak, F, Schull, M, Porch, Wendy, Bell, Sandi, Schull, Michael, Safar, Yousef, Lunsky, Yona, Katz, Gabrielle M, Cooper, J, Campanella, S   +26 more
core   +1 more source

Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial [PDF]

, 2022
Background: Open-label platform trials and a prospective meta-analysis suggest efficacy of anti–IL-6R therapies in hospitalized patients with COVID-19 receiving corticosteroids.
DiCioccio, A. Thomas, Saggar, Suraj, Herman, Gary A., Sivapalasingam, Sumathi, Aberg, Judith A., Kampman, Wendy, Ferreira, Manuel A., Kosmicki, Jack A., O'Brien, Meagan P., Boyapati, Anita, Criner, Gerard, Hosain, Romana, Labriola-Tompkins, Emily, Musser, Bret J., Akinlade, Bolanle, Brown, Samuel M., Bhore, Rafia, Ng Gong, Michelle, Horowitz, Julie E., Hajizadeh, Negin, Sobieszczyk, Magdalena E., Park, William, Gulabani, Daya, Yancopoulos, George D., Mahmood, Adnan, Lederer, David J., Sperber, Steven J., Weinrich, David M., Stein, David K., Baras, Aris, Giannelou, Angeliki, Menon, Vidya, Somersan-Karakaya, Selin, Purcell, Lisa A., Nivens, Michael C., Parrino, Janie, Kowal, Bari, Waldron, Alpana, Braunstein, Ned, Criner|, Ramesh, Divya   +40 more
core   +1 more source

Nigeria: The impact of COVID-19 and food system responses

, 2021
As Nigeria continues to face the effects of the COVID-19 pandemic, CGIAR and partners have expanded access to quality seeds and improved crop varieties, strengthened capacity of women and youth, and informed national responses and policies with evidence ...
COVID-19 Hub
core   +1 more source

Myanmar: The impact of COVID-19 and food system responses

, 2021
In Myanmar, the COVID-19 pandemic and political upheaval have both had significant economic and social repercussions. CGIAR has been working with partners in the country to assess the economic impacts of the pandemic and their consequences for agrifood ...
COVID-19 Hub
core   +1 more source

Bangladesh: The impact of COVID-19 and food system responses

, 2021
While Bangladesh has had reactionary responses to the newer waves of COVID-19, it is projected that the country could face severe consequences if the Delta variant detected in May 2021 spreads. Since the beginning of the health crisis, CGIAR and partners
COVID-19 Hub
core   +1 more source

Ethiopia: The impact of COVID-19 and food system responses

, 2021
In Ethiopia, the COVID-19 pandemic has affected livelihoods and caused declines in the gross domestic product (GDP) of the agrifood system (AFS) as well as in total GDP.
COVID-19 Hub
core   +1 more source

Malawi: The impact of COVID-19 and food system responses

, 2021
Malawi, like other southern African countries, has endured several waves of infection since the COVID-19 pandemic started. The disease has had severe effects on the economy, including the agriculture sector.
COVID-19 Hub
core   +1 more source

A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19

, 2021
BACKGROUND: Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate the inflammatory response in Covid-19. METHODS: We performed an adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab 200 ...
DiCioccio, A. Thomas, Saggar, Suraj, Sivapalasingam, Sumathi, Aberg, Judith A., Kampman, Wendy, Ferreira, Manuel A., Kosmicki, Jack A., Parrino, Jani, Boyapati, Anita, Criner, Gerard, Hosain, Romana, Labriola-Tompkins, Emily, Akinlade, Bolanle, Brown, Samuel M., Weinreich, David M., Bhore, Rafia, Ng Gong, Michelle, Horowitz, Julie E., Hajizadeh, Negin, Sobieszczyk, Magdalena E., Park, William, Gulabani, Daya, Yancopoulos, George D., Mahmood, Adnan, Lederer, David J., Sperber, Steven J., Musser, Bret, Stein, David K., Baras, Aris, Giannelou, Angeliki, Menon, Vidya, Somersan-Karakaya, Selin, O’Brien, Meagan, Purcell, Lisa A., Nivens, Michael C., Herman, Gary, Kowal, Bari, Waldron, Alpana, Braunstein, Ned, Ramesh, Divya   +39 more
core   +1 more source

Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

, 2022
BACKGROUND: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic coronavirus disease 2019 (COVID-19) is unclear. DESIGN: ACTIV-6 is an ongoing, decentralized,
Boulware, David R., Stewart, Thomas G., Adam, Stacey J., Castro, Mario, Lindsell, Christopher J., Hanna, George, Ruiz-Unger, Juan, Singh, Upinder, Gentile|, Hernandez, Adrian F., Wilder, Rhonda, Thicklin, Florence, McTigue, Kathleen, Ginde, Adit A., Bramante, Carolyn, DeLong, Allison, Felker, G. Michael, Dolor, Rowena J., McCarthy, Matthew W., Wilson, Sybil, Sulkowski, Mark, Collins, Sean, Dunsmore, Sarah E., Jayaweera, Dushyantha, Remaly, April, Gentile, Nina, Naggie, Susanna, Shenkman, Elizabeth   +27 more
core   +1 more source